The DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index.
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease
Open accessAbstract
Chronic kidney disease (CKD) is associated with a high risk of death from coronary artery disease and may modify the response to standard cardiovascular therapies. Treatment of subjects with CKD should ideally be based on evidence from randomized, clinical trials, but how often subjects with CKD have been excluded from these trials is uncertain. We undertook this study in order to quantify how often subjects with moderate to advanced CKD were excluded from large cardiovascular trials. MEDLINE and the reference list of selected articles were searched in order to identify large, randomized, controlled trials of five different coronary artery disease therapies published between 1998 and 2005. Exclusion criteria and reported clinical characteristics of subjects were abstracted. Rates of exclusion and reporting of baseline characteristics of study participants were compared for CKD, diabetes, history of smoking, and hypertension. Eighty-six trials randomizing 411 653 patients were identified. More than 80% of trials excluded subjects with end-stage renal disease and 75.0% excluded patients with CKD. Subjects with diabetes, hypertension, or a history of smoking were excluded less than 4% of the time. Baseline renal function of study participant was reported in only 7% of trials. Patients with CKD are frequently excluded from coronary artery disease trials and renal function of randomized subjects is rarely reported. These findings reinforce the notion that available data on the tre…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [24]
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O’Shaughnessy, C. D., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,222
Self-citation
Research works printed but not linked: 1
- Gilbertson, 2003, Projecting the US ESRD population to 2030, J Am Soc Nephrol, 14, F-PO881
Cited by
Sorted by citations
Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32064-5 · Cited by 3,842
Herzog, C. A., ASINGER, R. W., Berger, A. K., Charytan, D. M., Dı́ez, J., Hart, R. G., Eckardt, K., Kasiske, B. L., McCullough, P. A., PASSMAN, R. S., et al. (2011) · Kidney International · doi:10.1038/ki.2011.223 · Cited by 934
Self-citationManagement of coronary disease in patients with advanced kidney disease
Bangalore, S., Maron, D. J., O’Brien, S. M., Fleg, J. L., Kretov, E. I., Briguori, C., Kaul, U., Reynolds, H. R., Mazurek, T., Sidhu, M. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915925 · Cited by 499
Cardiorenal Syndrome Revisited
Zannad, F. M., & Rossignol, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028814 · Cited by 351
Turakhia, M. P., Blankestijn, P. J., Carrero, J. J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., PASSMAN, R. S., Pecoits‐Filho, R., Reinecke, H., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy060 · Cited by 297
Self-citation
Metadata
- Authors
- Charytan, D., & Kuntz, R. E.
- Affiliations
- Brigham and Women's Hospital (US)
- Medtronic (United States) (US)
- Corresponding author
- Charytan, D.
- ORCID
- Charytan, D.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 70
- Issue
- 11
- Pages
- 2021-2030
- ISSN
- 0085-2538 (ISSN-L)
- PMC
- PMC2950017
- OpenAlex
- W2030060276
- Cited by
- 271
- References
- 117
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 24 · 2023: 19 · 2022: 17 · 2021: 24 · 2020: 24 · 2019: 13 · 2018: 17 · 2017: 18 · 2016: 11 · 2015: 9 · 2014: 14 · 2013: 10 · 2012: 11
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (T32 DK007527-22)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- chronic kidney disease, coronary artery disease, exclusion criteria, inclusion and exclusion criteria, end-stage renal disease, diabetes mellitus, hypertension, smoking history, cardiovascular disease treatment, generalizability of trial results
- MeSH terms
- Adrenergic beta-Antagonists, Clinical Trials as Topic, Coronary Artery Disease, Humans, Platelet Aggregation Inhibitors, Patient Selection, Platelet Glycoprotein GPIIb-IIIa Complex, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
